Cangene cuts jobs and execs on lower US government orders
This article was originally published in Scrip
Executive Summary
Cangene, one of Canada's longest-standing biopharma companies, has announced the departure of two senior executives and a workforce reduction of around 17%. The cuts come in the face of reduced orders from the US government for its bio-defence stockpiles, and following the appointment last September of CEO John Sedor, who wants to help the company "recreate its entrepreneurial culture".